NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

Company Overview

NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $0.59 to $0.62
• 50-Day Range: $0.57 to $0.69
• 52-Week Range: $0.44 to $1.01
• Volume: 1,662 shs
• Average Volume: 107,401 shs
• Market Capitalization: $3.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed this year?

NovaBay Pharmaceuticals' stock was trading at $0.58 on January 1st, 2025. Since then, NBY shares have increased by 5.0% and is now trading at $0.6090.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its quarterly earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by $0.35. The biopharmaceutical company had revenue of $1.84 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 380.67% and a negative net margin of 69.35%.

When did NovaBay Pharmaceuticals' stock split?

Shares of NovaBay Pharmaceuticals reverse split on Wednesday, November 16th 2022.The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), Tesla (TSLA) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 8/18/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:NBY
• CIK: 1389545
• Web: novabay.com
• Phone: (510) 899-8800
• Fax: 510-474-1577
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($9.9465)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.22 million
• Net Margins: -69.35%
• Pretax Margin: -77.86%
• Return on Equity: -380.67%
• Return on Assets: -157.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.95
• Quick Ratio: 2.95

Sales & Book Value

• Annual Sales: $9.78 million
• Price / Sales: 0.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.03) per share
• Price / Book: -20.58

Miscellaneous

• Outstanding Shares: 5,820,000
• Free Float: 5,810,000
• Market Cap: $3.59 million
• Optionable: Not Optionable
• Beta: 0.40